ArticleRadiology2012
Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target.
Article in Radiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 94 citations in OpenAlex.
- Complementary PET and MRI of myeloperoxidase activity as a noninvasive surrogate for tissue acrolein in experimental neuroinflammation.NeuroImage · 2026Article
- Evaluation of phenyl hydrazide-based compounds as myeloperoxidase inhibitors.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Restoring the Multiple Sclerosis Associated Imbalance of Gut Indole Metabolites Promotes Remyelination and Suppresses Neuroinflammation.bioRxiv : the preprint server for biology · 2025Article
- Quantitative in Vivo Molecular MRI.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Targeting myeloperoxidase to stabilize unruptured aneurysm: an imaging-guided approach.BMC cardiovascular disorders · 2024Article
- Changes in the Expression of Proteins Associated with Neurodegeneration in the Brains of Mice after Infection with Influenza A Virus with Wild Type and Truncated NS1.International journal of molecular sciences · 2024Article
- Neutrophils in Inflammatory Diseases: Unraveling the Impact of Their Derived Molecules and Heterogeneity.Cells · 2023Review
- Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma.Journal for immunotherapy of cancer · 2023Article
- Optimizing animal models of autoimmune encephalitis using active immunization.Frontiers in immunology · 2023Article
- Neutrophil Extracellular Traps in Cerebral Ischemia/Reperfusion Injury: Friend and Foe.Current neuropharmacology · 2023Review
- Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy.Neoplasia (New York, N.Y.) · 2022Article
- Evaluation of Myeloperoxidase as Target for Host-Directed Therapy in Tuberculosis In Vivo.International journal of molecular sciences · 2022Article
- Molecular immuno-imaging improves tumor detection in head and neck cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- The role of neutrophils in the dysfunction of central nervous system barriers.Frontiers in aging neuroscience · 2022Review
- d-mannose suppresses oxidative response and blocks phagocytosis in experimental neuroinflammation.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Identification of potential oxidative stress biomarkers for spinal cord injury in erythrocytes using mass spectrometry.Neural regeneration research · 2021Article
- Highly Efficient Activatable MRI Probe to Sense Myeloperoxidase Activity.Journal of medicinal chemistry · 2021Article
- Myeloid cell-derived HOCl is a paracrine effector that trans-inhibits IKK/NF-κB in melanoma cells and limits early tumor progression.Science signaling · 2021Article
- Inhibition of Myeloperoxidase.Handbook of experimental pharmacology · 2021Article
- Myeloperoxidase instigates proinflammatory responses in a cecal ligation and puncture rat model of sepsis.American journal of physiology. Heart and circulatory physiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeTo evaluate myeloperoxidase (MPO) as a newer therapeutic target and bis-5-hydroxytryptamide-diethylenetriaminepentaacetate-gadolinium (Gd) (MPO-Gd) as an imaging biomarker for demyelinating diseases such as multiple sclerosis (MS) by using experimental autoimmune encephalomyelitis (EAE), a murine model of MS. MATERIALS AND
methodsAnimal experiments were approved by the institutional animal care committee. EAE was induced in SJL mice by using proteolipid protein (PLP), and mice were treated with either 4-aminobenzoic acid hydrazide (ABAH), 40 mg/kg injected intraperitoneally, an irreversible inhibitor of MPO, or saline as control, and followed up to day 40 after induction. In another group of SJL mice, induction was performed without PLP as shams. The mice were imaged by using MPO-Gd to track changes in MPO activity noninvasively. Imaging results were corroborated by enzymatic assays, flow cytometry, and histopathologic analyses. Significance was computed by using the t test or Mann-Whitney U test.
resultsThere was a 2.5-fold increase in myeloid cell infiltration in the brain (P = .026), with a concomitant increase in brain MPO level (P = .0087). Inhibiting MPO activity with ABAH resulted in decrease in MPO-Gd-positive lesion volume (P = .012), number (P = .009), and enhancement intensity (P = .03) at MR imaging, reflecting lower local MPO activity (P = .03), compared with controls. MPO inhibition was accompanied by decreased demyelination (P = .01) and lower inflammatory cell recruitment in the brain (P < .0001), suggesting a central MPO role in inflammatory demyelination. Clinically, MPO inhibition significantly reduced the severity of clinical symptoms (P = .0001) and improved survival (P = .0051) in mice with EAE.
conclusionMPO may be a key mediator of myeloid inflammation and tissue damage in EAE. Therefore, MPO could represent a promising therapeutic target, as well as an imaging biomarker, for demyelinating diseases and potentially for other diseases in which MPO is implicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.